Exploring formulation options for extended release minitablets
European Journal of Pharmaceutics and Biopharmaceutics · 2026
DOI: 10.1016/j.ejpb.2026.115145 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2026. Verfasst von Esther Bochmann und 7 weiteren Autor:innen. Beteiligte Einrichtung: Abbvie Deutschland GmbH & Co. KG, Drug Product Design & Development, Ludwigshafen, Germany. Electronic address: esther.bochmann@abbvie.com. Hauptthemen laut MEDLINE: Delayed-Action Preparations, Tablets. Die Arbeit nennt 29 Literaturangaben. Gefördert von: AbbVie Deutschland GmbH & Co KG.
Abstract (Originalsprache)
Compared to conventional tablets, minitablets have several advantages, like acceptance for patients with swallowing difficulties (from pediatric to geriatric) and high flexibility in dosing. Despite these advantages, minitablets are challenging for extended release (ER) dosage forms. We explored different ER minitablet formulations for Compound A with the aim of maintaining drug plasma concentrations over 24 h. Compound A is a BCS class II drug with pH-dependent solubility and was available as monosodium monohydrate salt and its parent free acid form. To reduce pill burden, high drug load in the final drug product was in scope. Minitablets were manufactured by either wet or melt granulation. The formulation screening was based on compendial dissolution testing to enable sufficient throughput. Subsequently, the impact of certain physiological luminal pH on drug release was explored in a biorelevant test method (multi-stage dissolution test). We demonstrated that by combining the right API form, hydrophobic matrix formers as well as hydrophilic release components, minitablets that enable the extended release of Compound A over 24 h were feasible. A defined material-sparing pathway to adjust release profiles combined with targeted biorelevant drug release testing provides a novel approach to develop ER minitablets in a relatively short time.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Abbvie Deutschland GmbH & Co. KG, Drug Product Design & Development, Ludwigshafen, Germany. Electronic address: esther.bochmann@abbvie.com.
- Abbvie Deutschland GmbH & Co. KG, Small Molecule Analytical R&D, Ludwigshafen, Germany.
- Abbvie Inc., Small Molecule Drug Product Development, Lake County, USA.
- Abbvie Deutschland GmbH & Co. KG, Drug Product Design & Development, Ludwigshafen, Germany.
- Abbvie Inc., CMC Strategy, Lake County, USA.
Förderung
- AbbVie Deutschland GmbH & Co KG
Zitieren
APA
Bochmann, E., Eugenieva-Ilieva, E., Heil, S., Katz, J. M., Koziolek, M., Marmol, A. L., Sanzgiri, Y., & Westedt, U. (2026). Exploring formulation options for extended release minitablets. European Journal of Pharmaceutics and Biopharmaceutics. https://doi.org/10.1016/j.ejpb.2026.115145
Vancouver
Bochmann E, Eugenieva-Ilieva E, Heil S, Katz JM, Koziolek M, Marmol AL, et al. Exploring formulation options for extended release minitablets. European Journal of Pharmaceutics and Biopharmaceutics. 2026. doi:10.1016/j.ejpb.2026.115145
BibTeX
@article{Bochmann2026,
author = {Bochmann, Esther and Eugenieva-Ilieva, Eugenia and Heil, Stephan and Katz, Jeffrey M and Koziolek, Mirko and Marmol, Alvaro Lopez and Sanzgiri, Yeshwant and Westedt, Ulrich},
title = {Exploring formulation options for extended release minitablets},
journal = {European Journal of Pharmaceutics and Biopharmaceutics},
year = {2026},
doi = {10.1016/j.ejpb.2026.115145}
}
EUVIMED